Sodium-glucose co-transporter-2 inhibitors in the intensive care unit setting: Do we really need sodium increase, especially in sepsis?
作者信息
Patoulias Dimitrios
机构信息
Second Department of Internal Medicine, European Interbalkan Medical Center, Thessaloniki, Greece.
出版信息
Crit Care. 2023 May 26;27(1):204. doi: 10.1186/s13054-023-04501-x.
Abstract
摘要
相似文献
1
Sodium-glucose co-transporter-2 inhibitors in the intensive care unit setting: Do we really need sodium increase, especially in sepsis?重症监护病房中钠-葡萄糖协同转运蛋白2抑制剂：我们真的需要增加钠含量吗，尤其是在脓毒症患者中？
Crit Care. 2023 May 26;27(1):204. doi: 10.1186/s13054-023-04501-x.
2
Sodium-glucose co-transporter-2 inhibitors in the intensive care unit setting: do we really need sodium increase, especially in sepsis? Reply.重症监护病房中钠-葡萄糖协同转运蛋白2抑制剂：我们真的需要提高血钠水平吗，尤其是在脓毒症患者中？回应
Crit Care. 2023 Jun 8;27(1):225. doi: 10.1186/s13054-023-04513-7.
3
Meta-Analysis Evaluating the Effect of Sodium-Glucose Co-Transporter-2 Inhibitors on Pulmonary Artery Pressure Indices.评估钠-葡萄糖协同转运蛋白2抑制剂对肺动脉压力指数影响的Meta分析
Am J Cardiol. 2022 Jun 1;172:169-170. doi: 10.1016/j.amjcard.2022.03.009. Epub 2022 Apr 2.
4
Effect of sodium-glucose co-transporter-2 inhibitors on right ventricular function in patients with type 2 diabetes mellitus: A pilot study.钠-葡萄糖协同转运蛋白2抑制剂对2型糖尿病患者右心室功能的影响：一项初步研究。
Kardiol Pol. 2022;80(6):696-698. doi: 10.33963/KP.a2022.0104. Epub 2022 Apr 21.
5
Sodium-glucose co-transporter-2 inhibitors, gut microbiota, and atherosclerotic cardiovascular disease: Another mountain to conquer?钠-葡萄糖协同转运蛋白2抑制剂、肠道微生物群与动脉粥样硬化性心血管疾病：又一座有待攻克的高峰？
Pharmacol Res. 2023 Jan;187:106619. doi: 10.1016/j.phrs.2022.106619. Epub 2022 Dec 16.
6
A meta-analysis of randomized controlled trials evaluating sodium-glucose co-transporter 2 inhibitors and incidental atrial fibrillation-Is there a true benefit?一项评估钠-葡萄糖协同转运蛋白2抑制剂与偶发性心房颤动的随机对照试验的荟萃分析——真的有益处吗？
Diabetes Metab Res Rev. 2024 Jan;40(1):e3715. doi: 10.1002/dmrr.3715. Epub 2023 Aug 30.
7
Impact of SGLT2 inhibitors on the kidney in people with type 2 diabetes and severely increased albuminuria.SGLT2 抑制剂对 2 型糖尿病合并严重白蛋白尿患者肾脏的影响。
Expert Rev Clin Pharmacol. 2022 Jul;15(7):827-842. doi: 10.1080/17512433.2022.2108402. Epub 2022 Aug 22.
8
Sodium-glucose co-transporter 2 inhibition: the saga continues.钠-葡萄糖协同转运蛋白2抑制剂：故事仍在继续。
Eur Heart J. 2022 Nov 1;43(41):4215-4218. doi: 10.1093/eurheartj/ehac590.
9
How to position sodium-glucose co-transporter 2 inhibitors in the management of diabetes in acromegaly patients.如何在肢端肥大症患者的糖尿病管理中定位钠-葡萄糖协同转运蛋白2抑制剂。
Endocrine. 2023 Jun;80(3):491-499. doi: 10.1007/s12020-023-03352-4. Epub 2023 Mar 31.
10
Liver autophagy-induced valine and leucine in plasma reflect the metabolic effect of sodium glucose co-transporter 2 inhibitor dapagliflozin.血浆中肝自噬诱导的缬氨酸和亮氨酸反映了钠-葡萄糖共转运蛋白 2 抑制剂达格列净的代谢作用。
EBioMedicine. 2022 Dec;86:104342. doi: 10.1016/j.ebiom.2022.104342. Epub 2022 Nov 21.
引用本文的文献
1
Sodium-glucose co-transporter-2 inhibitors in the intensive care unit setting: do we really need sodium increase, especially in sepsis? Reply.重症监护病房中钠-葡萄糖协同转运蛋白2抑制剂：我们真的需要提高血钠水平吗，尤其是在脓毒症患者中？回应
Crit Care. 2023 Jun 8;27(1):225. doi: 10.1186/s13054-023-04513-7.
本文引用的文献
1
Sodium glucose co-transporter-2 inhibitors in intensive care unit patients with type 2 diabetes: a pilot case control study.钠-葡萄糖共转运蛋白 2 抑制剂在 2 型糖尿病重症监护病房患者中的应用：一项初步的病例对照研究。
Crit Care. 2023 May 16;27(1):189. doi: 10.1186/s13054-023-04481-y.
2
Hypernatremia and moderate-to-severe hyponatremia are independent predictors of mortality in septic patients at emergency department presentation: A sub-group analysis of the need-speed trial.高钠血症和中重度低钠血症是急诊科就诊脓毒症患者死亡的独立预测因子：需要速度试验的亚组分析。
Eur J Intern Med. 2021 Jan;83:21-27. doi: 10.1016/j.ejim.2020.10.003. Epub 2020 Nov 5.
3
ICU-Acquired Hypernatremia Is Associated with Persistent Inflammation, Immunosuppression and Catabolism Syndrome.重症监护病房获得性高钠血症与持续性炎症、免疫抑制和分解代谢综合征相关。
J Clin Med. 2020 Sep 18;9(9):3017. doi: 10.3390/jcm9093017.
4
Risk Factors and Outcomes in Patients With Hypernatremia and Sepsis.高钠血症合并脓毒症患者的危险因素及预后
Am J Med Sci. 2016 Jun;351(6):601-5. doi: 10.1016/j.amjms.2016.01.027. Epub 2016 Mar 31.
5
Intensive care unit-acquired hypernatremia is an independent predictor of increased mortality and length of stay.重症监护病房获得性高钠血症是死亡率和住院时间增加的独立预测因素。
J Crit Care. 2013 Aug;28(4):405-12. doi: 10.1016/j.jcrc.2012.11.013. Epub 2013 Jan 29.
Zotero 插件